FC
NVAX icon

Financial Consulate’s Novavax NVAX Stock Holding History

Financial Consulate’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24K Hold
398
– – ﹤0.01% 880
2025
Q4 		$2.67K Hold
398
– – ﹤0.01% 842
2025
Q3 		$3.45K Buy
+398
New +$3.1K ﹤0.01% 717

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Consulate's NVAX Position: Q1 2026 in Review

Financial Consulate held its Novavax (NVAX) position steady in Q1 2026 at 398 shares worth $3.24K. The position accounts for ﹤0.01% of the portfolio, ranked #880.

Financial Consulate first reported a position in NVAX in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.45K in Q3 2025. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Financial Consulate held 398 shares of Novavax worth $3.24K as of Q1 2026.
  • Financial Consulate left its Novavax share count unchanged in Q1 2026.
  • Novavax made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #880 holding.
  • Financial Consulate first reported a position in Novavax in Q3 2025 and has held it in 3 quarters since.
  • Financial Consulate's Novavax position peaked at $3.45K in Q3 2025.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.